Live Breaking News & Updates on As Azn Gb0009895292

Stay updated with breaking news from As azn gb0009895292. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

AstraZeneca's Ultomiris approved in EU for autoimmune disease NMOSD

AstraZeneca PLC on Wednesday said the European Commission approved its drug Ultomiris in the EU for adults with autoimmune disease neuromyelitis optica spectrum disorder, known as NMOSD.

The. | May 10, 2023 ....

City Of , United Kingdom , Orhan Aktas , Marc Dunoyer , Tom Budszus , Alliance News Ltd , Alliance News , Department Of Neurology , European Commission , Alexion Pharmaceuticals , Medical Faculty , All Rights , Astrazeneca Plc Stock Exchange , Press Release , As Azn Gb0009895292 ,

AstraZeneca's Tezspire Recommended for EU Approval in Asthma Treatment

By Kyle Morris


AstraZeneca PLC said Monday that Tezspire has been recommended for approval in the EU for the treatment of severe asthma.

The pharmaceutical giant said Tezspire has been. | July 25, 2022 ....

Kyle Morris , European Union , Medicinal Products , Human Use , European Medicines Agency , Dow Jones , Astrazeneca Plc Stock Exchange , Press Release , As Azn Gb0009895292 ,

Britain approves AstraZeneca's antibody-based COVID therapy

-Britain s medicines regulator has approved AstraZeneca s antibody-based COVID-19 treatment for adults with poor immune response, marking a major step in the fight against the pandemic as infections. | March 17, 2022 ....

United States , United Kingdom , David Goodman , Pushkala Aripaka , World Health Organization , Regulatory Agency , Anild Silva , Astrazeneca Plc Stock Exchange , Press Release , As Azn Gb0009895292 ,